Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
1.2.1 Phase I – Secondary Research
1.2.2 Phase II – Primary Research
1.2.3 Phase III – Expert Panel Review
1.2.4 Assumptions
Chapter 2 Executive Summary
2.1 Global Peripheral Neuropathy Market Portraiture
2.2 Global Peripheral Neuropathy Market Revenue, by Treatment, 2016 Vs 2025, (Value %)
2.3 Global Peripheral Neuropathy Market Revenue, by Geography, 2016, (US$ Million)
Chapter 3 Global Peripheral Neuropathy Market Analysis
3.1 Peripheral Neuropathy Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Growing prevalence of diabetes and cancer
3.2.1.2 Growing preference for non-pharmacological modalities
3.2.2 Challenges
3.2.2.1 Challenge of Developing New Pain Medications for Neuropathic Pain
3.2.2.2 High treatment rate as against low satisfaction indicate gap in treatment
3.2.3 Opportunities
3.2.3.1 Development of drugs with selective targeting of ion channels
3.3 Attractive Investment Proposition
3.4 Market Positioning of Key Players in Global Peripheral Neuropathy Market
Chapter 4 Global Peripheral Neuropathy Market, by Treatment Type
4.1 Overview
4.2 Pharmacological Therapies
4.2.1 Pain Relievers
4.2.1.1 Tramadol
4.2.1.2 Oxycodone
4.2.1.3 Cylcooxgenase Inhibitors
4.2.1.4 Corticosteroid
4.2.2 Anti-seizure medications
4.2.2.1 Gabapentin
4.2.2.2 Pregabalin
4.2.3 Antidepressants
4.2.3.1 Amitriptyline
4.2.3.2 Doxepin
4.2.3.3 Nortriptyline
4.2.3.4 Duloxetine
4.2.3.5 Venlafaxine
4.3 Non-Pharmacological Therapies
4.3.1 Transcutaneous electrical nerve stimulation
4.3.2 Plasma exchange and intravenous immune globulin
4.3.3 Others(Physical Therapy and Surgery)
Chapter 5 Global Peripheral Neuropathy Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, and Rest of APAC)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.6 Middle East and Africa (UAE, Saudi Arabia and South Africa)
Chapter 6 Company Profiles
6.1 Abbott Laboratories
6.2 Bristol Myers Squibb
6.3 Cipla Limited
6.4 Eli Lilly and Company
6.5 GlaxoSmithKline plc.
6.6 Lupin Limited
6.7 Merck and Co. Inc.
6.8 Novartis
6.9 Pfizer Inc.
6.10 Dr. Reddy’s Laboratories
List of Figures
FIG. 1 Global Peripheral Neuropathy Market: Research Methodology
FIG. 2 Global Peripheral Neuropathy Market Revenue, by Treatment, 2016 Vs 2025 (Value %)
FIG. 3 Global Peripheral Neuropathy Market Revenue, by Geography, 2016 (US$ Million)
FIG. 4 Attractive Investment Proposition: Global Peripheral Neuropathy Market, by Region
FIG. 5 Market Positioning of Key Players: Global Peripheral Neuropathy Market
FIG. 6 Tramadol Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 7 Oxycodone Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 8 Cylcooxgenase Inhibitors Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 9 Corticosteroid Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 10 Gabapentin Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 11 Pregabalin Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 12 Amitriptyline Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 13 Doxepin Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 14 Nortriptyline Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 15 Duloxetine Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 16 Venlafaxine Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 17 Transcutaneous Electrical Nerve Stimulation Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 18 Plasma Exchange and Intravenous Immune Globulin Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 19 Others (Physical Therapy and Surgery) Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 20 Latin America Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
FIG. 21 Middle East & Africa Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
List of Tables
TABLE 1 Global Peripheral Neuropathy Market, by Treatment Type, 2015 – 2025 (US$ Mn)
TABLE 2 Pharmacological Therapies Global Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
TABLE 3 Pain Relievers Global Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
TABLE 4 Anti-seizure Medications Global Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
TABLE 5 Antidepressant Global Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
TABLE 6 Non- Pharmacological Therapies Global Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
TABLE 7 Global Peripheral Neuropathy Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 8 North America Peripheral Neuropathy Market , by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Europe Peripheral Neuropathy Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Asia-Pacific Peripheral Neuropathy Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Abbott Laboratories: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 12 Bristol Myers Squibb: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 13 Cipla Limited.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 14 Eli Lilly and Company: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 15 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 16 Lupin Limited.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 17 Merck and Co. Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 18 Novartis: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 19 Pfizer Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 20 Dr. Reddy’s Laboratories: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)